Refanezumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Refanezumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetmyelin-associated glycoprotein
Clinical data
SynonymsGSK249320
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6608H10156N1732O2064S44
Molar mass148.3 kg/mol g·mol−1

Refanezumab (GSK249320) is a monoclonal antibody designed for the recovery of motor function after stroke.[1]

This drug was developed by GlaxoSmithKline.

References[edit]